尼达尼布在间质性肺疾病患者中按性别分亚组的安全性与耐受性:四项随机对照试验汇总数据的事后分析
该事后分析汇总INPULSIS、SENSCIS和INBUILD四项随机对照试验数据,评估尼达尼布在自身免疫病相关间质性肺疾病(ILD)和其他ILD患者中按性别分亚组的不良事件。结果显示女性患者恶心、呕吐、肝酶升高、剂量减少和治疗中断的发生率高于男性,但导致停药的不良事件比例在自身免疫病相关ILD中两性相似。作者认为在监测和管理尼达尼布相关不良事件时应考虑性别。
要点
- 自身免疫病相关ILD中,女性尼达尼布治疗者恶心34%、呕吐27%,高于男性21%、12%。
- 其他ILD中,女性尼达尼布治疗者恶心40%、呕吐30%,高于男性21%、8%。
- 腹泻是尼达尼布治疗中最常见的不良事件,也是导致停药最常见的事件。
核心结论
- 尼达尼布的不良事件特征在自身免疫病相关ILD和其他ILD的男女性患者间总体相似,但女性患者恶心、呕吐、肝酶升高、剂量减少和治疗中断更频繁。
- 作者认为在监测和管理可能与尼达尼布相关的不良事件时应考虑性别。
研究设计与样本
- 事后分析,汇总两项INPULSIS试验(特发性肺纤维化)、SENSCIS试验(系统性硬化症相关纤维化ILD)和INBUILD试验(非特发性肺纤维化的进展性纤维化ILD)的数据。
- 各试验中患者随机接受口服尼达尼布150 mg每日两次或匹配安慰剂。
- 分析纳入自身免疫病相关ILD患者746例(女性523例[70%],男性223例[30%];615例[82%]患系统性硬化症),其中370例(50%)接受尼达尼布(女性268例[72%],男性102例[28%]),376例(50%)接受安慰剂(女性255例[68%],男性121例[32%])。
- 分析纳入其他ILD患者1554例(女性437例[28%],男性1117例[72%];1061例[68%]患特发性肺纤维化),其中888例(57%)接受尼达尼布(女性237例[27%],男性651例[73%]),666例(43%)接受安慰剂(女性200例[30%],男性466例[70%])。
- 评估52周内报告的不良事件。
主要发现
- 自身免疫病相关ILD尼达尼布治疗者中,恶心报告于男性21例(21%)和女性92例(34%),呕吐报告于男性12例(12%)和女性73例(27%)。
- 自身免疫病相关ILD尼达尼布治疗者中,丙氨酸氨基转移酶升高报告于男性4例(4%)和女性31例(12%),天冬氨酸氨基转移酶升高报告于男性3例(3%)和女性23例(9%)。
- 自身免疫病相关ILD尼达尼布治疗者中,导致剂量减少的不良事件报告于男性18例(18%)和女性101例(38%);至少一次治疗中断见于男性28例(27%)和女性107例(40%)。
- 其他ILD尼达尼布治疗者中,恶心报告于男性135例(21%)和女性95例(40%),呕吐报告于男性51例(8%)和女性70例(30%)。
- 其他ILD尼达尼布治疗者中,丙氨酸氨基转移酶升高报告于男性19例(3%)和女性31例(13%),天冬氨酸氨基转移酶升高报告于男性17例(3%)和女性26例(11%);导致剂量减少的不良事件报告于男性106例(16%)和女性84例(35%);至少一次治疗中断见于男性155例(24%)和女性82例(35%)。
关键数值与推荐
- 自身免疫病相关ILD中,导致尼达尼布停药的不良事件比例女性44例(16%)/268例 vs 男性17例(17%)/102例,两性相似。
- 其他ILD中,导致尼达尼布停药的不良事件比例女性62例(26%)/237例 vs 男性112例(17%)/651例,女性高于男性。
- 腹泻是与尼达尼布相关的最常见不良事件:自身免疫病相关ILD中女性198例(74%)/268例、男性73例(72%)/102例;其他ILD中女性155例(65%)/237例、男性408例(63%)/651例。
- 腹泻也是最常导致治疗停药的事件:自身免疫病相关ILD中女性20例(7%)、男性5例(5%);其他ILD中女性16例(7%)、男性27例(4%)。
临床怎么用
- 作者认为在监测和管理可能与尼达尼布相关的不良事件时应考虑性别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nintedanib is a tyrosine kinase inhibitor used in the treatment of progressive fibrosing interstitial lung diseases (ILDs). We assessed the safety and tolerability of nintedanib in patients with autoimmune disease-related ILDs and with other ILDs in subgroups by sex. METHODS: In this post-hoc analysis, we pooled data from the two INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF), the SENSCIS trial in patients with fibrosing ILDs associated with systemic sclerosis, and the INBUILD trial in patients with progressive fibrosing ILDs other than IPF. In each trial, patients were randomly assigned to receive oral nintedanib 150 mg twice daily or matched placebo. We assessed adverse events reported over 52 weeks in patients with autoimmune disease-related ILDs and other ILDs in subgroups by sex. FINDINGS: In these analyses, we included 746 patients with autoimmune disease-related ILDs (523 [70%] were female, 223 [30%] were male; 615 [82%] had systemic sclerosis), of whom 370 (50%) received nintedanib (268 [72%] female and 102 [28%] male patients) and 376 (50%) received placebo (255 [68%] female and 121 [32%] male patients); and 1554 patients with other ILDs (437 [28%] female, 1117 [72%] male; 1061 [68%] with IPF), of whom 888 (57%) received nintedanib (237 [27%] female and 651 [73%] male patients) and 666 (43%) received placebo (200 [30%] female and 466 [70%] male patients). Of 102 male and 268 female patients with autoimmune disease-related ILDs treated with nintedanib, nausea was reported in 21 (21%) male and 92 (34%) female patients, vomiting in 12 (12%) male and 73 (27%) female patients, alanine aminotransferase increase in four (4%) male and 31 (12%) female patients, aspartate aminotransferase increase in three (3%) male and 23 (9%) female patients, and adverse events leading to dose reduction in 18 (18%) male and 101 (38%) female patients; 28 (27%) male and 107 (40%) female patients had at least one treatment interruption. Of 651 male and 237 female nintedanib-treated patients with other ILDs, nausea was reported in 135 (21%) male and 95 (40%) female patients, vomiting in 51 (8%) male and 70 (30%) female patients, alanine aminotransferase increase in 19 (3%) male and 31 (13%) female patients, aspartate aminotransferase increase in 17 (3%) male and 26 (11%) female patients, and adverse events leading to dose reduction in 106 (16%) male and 84 (35%) female patients; 155 (24%) male and 82 (35%) female patients had at least one treatment interruption. The proportions of patients with adverse events leading to discontinuation of nintedanib were similar between female and male patients with autoimmune disease-related ILDs (44 [16%] of 268 vs 17 [17%] of 102), but were greater among female than male patients with other ILDs (62 [26%] of 237 vs 112 [17%] of 651). Across subgroups by diagnosis and sex, diarrhoea was the most frequent adverse event associated with nintedanib (autoimmune-related ILDs: 198 [74%] of 268 female and 73 [72%] of 102 male patients; other ILDs: 155 [65%] of 237 female and 408 [63%] of 651 male patients), and was the event that most frequently led to treatment discontinuation (autoimmune-related ILDs: 20 [7%] female and five [5%] male patients; other ILDs: 16 [7%] female and 27 [4%] male patients). INTERPRETATION: The adverse event profile of nintedanib was generally similar between male and female patients with autoimmune disease-related ILDs, and between male and female patients with other ILDs, but nausea, vomiting, liver enzyme elevations, dose reductions, and treatment interruptions were more frequent in female patients than in male patients. Sex should be considered in the monitoring and management of adverse events that might be associated with nintedanib. FUNDING: Boehringer Ingelheim.
引用
- Hoffmann-Vold AM, Volkmann ER, Allanore Y, et al. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials. Lancet Rheumatol. 2022. PMID: 38265966. doi:10.1016/S2665-9913(22)00215-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。